All Categories
  • All Categories
  • Accessories
  • Accessories & More
  • Butters & Eggs
  • Camera & Video
  • Mornitors
  • Tablets
  • Laptops
  • Handbags
  • Headphone & Speaker
  • Herbs & botanicals
  • Vegetables
  • Shop
  • Laptops & Desktops
  • Watchs
  • Electronic

Blog archive

2020

Sugammadex

Sugammadex is used to reverse neuromuscular blockade after administration of the amino steroid non-depolarizing neuromuscular-blocking agents such as Vecuronium or Rocuronium. It is the first selective relaxant binding agent (SRBA). Sugammadex Sodium is the sodium salt form of the biologically inert, selective relaxant binding agent (SRBA) sugammadex, a modified, anionic cyclodextrin derivative containing a hydrophilic exterior and a hydrophobic core, with neuromuscular blocking drug (NMBD) reversal activity.

DEXAMETHASONE

Dexamethasone is used to treat conditions such as arthritis, blood/hormone/immune system disorders, allergic reactions, certain skin and eye conditions, breathing problems, certain bowel disorders, and certain cancers. Recently it is being hailed as a wonder cure for Covid-19 after the study group conducting a clinical trial in United Kingdom. A drug named dexamethasone is the talk of the hour given recent claims that it can cut mortality in patients with severe forms of COVID-19 by a third. In COVID-19 patients, dexamethasone serves to dampen the body’s immune response when it becomes too aggressive to control by other means.

Pharmaceutical Reference Standards available for COVID-19 Research Projects

Hydroxychloroquine # The antimalarial drug chloroquine and its safer derivative hydroxychloroquine are commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. These drugs have also attracted attention over the past few decades as a potential antiviral agent, currently as a possible treatment for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19. Reports found that chloroquine could inhibit SARS-CoV-2 in vitro, and showed apparent efficacy in treating COVID-19 in humans. The US Food and Drug Administration has designated hydroxychloroquine for off-label, compassionate use for treating COVID-19, and WHO added the drug to its large global solidarity trial to test a variety of potential treatments.